Copy to clipboard 
Exactech posted 2Q17 revenue of US $67.3MM, +1.8% vs. 2Q16, and 1H17 revenue of $136.8MM, +4.1% vs. 1H16.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Joint Reconstruction | $65.3 | $61.8 | $3.5 | 5.6% |
| Knee | $21.5 | $21.5 | $0.0 | 0.2% |
| Hip | $12.5 | $13.4 | -$1.0 | -7.2% |
| Extremities | $31.3 | $27.0 | $4.4 | 16.3% |
| Spine | $0.0 | $2.0 | -$2.0 | -100.0% |
| Orthobiologics | $2.0 | $2.3 | -$0.3 | -13.3% |
| Total | $67.3 | $66.1 | $1.2 | 1.8% |
| 1H17 | 1H16 | $ Change | % Change | |
| Joint Reconstruction | $132.6 | $122.9 | $9.7 | 7.9% |
| Knee | $43.6 | $43.3 | $0.3 | 0.8% |
| Hip | $25.6 | $25.8 | -$0.2 | -0.8% |
| Extremities | $63.4 | $53.8 | $9.6 | 17.8% |
| Spine | $0.3 | $3.8 | -$3.5 | -92.5% |
| Orthobiologics | $3.9 | $4.7 | -$0.8 | -16.9% |
| Total | $136.8 | $131.4 | $5.4 | 4.1%* |
*Excluding the impact of divested spine products, 1H17 growth would be 7%
2Q17 Geographic results: U.S. $45.6MM, +2.4%; ex-U.S. $21.6MM, +0.6%
Performance highlights:
- Recon extremities growth benefited somewhat from Vantage ankle pilot launch, as well as the Equinoxe Preserve humeral stem
- Hips negatively affected by price pressure and certain ex-U.S. distribution transitions: changing out a distributor, in one instance, and changing a business model in another
- Knee revenue offset by price decreases
- Ongoing pilot launches of Truliant knee, Alteon HA hip stem and ExactechGPS shoulder application progressing well
- Completed first Truliant procedures in mid-2Q, now over 150 surgeries in; logged first Equinoxe Preserve and Alteon hip stem procedures by quarter’s end
- In 2H17, will build inventory for Truliant knee, pursuing full launch by year-end
- At the very end of the quarter, entered pilot launch for ExactechGPS TKA PLUS
- Rotating Bearing Knee is still with FDA – no further updates yet
- Announced first clinical use in Japan of recently-approved systems, including the Optetrak Logic CR knee, Novation Crown Cup, Alteon Tapered Wedge Stem and Equinoxe Reverse Shoulder
- After quarter’s close, entered an agreement to sell 100% of its investment in Exactech Medical Shanghai to Double Medical Technology for cash proceeds of $1.6MM; at closing—expected in 2H17—will enter into a distribution agreement for Double Medical to market Exactech’s products in China
Source: Exactech, Inc.; Form 10-Q, SEC.gov
Exactech posted 2Q17 revenue of US $67.3MM, +1.8% vs. 2Q16, and 1H17 revenue of $136.8MM, +4.1% vs. 1H16.
Q17
Q16
$ Change
% Change
Joint Reconstruction
$65.3
$61.8
$3.5 ...
Exactech posted 2Q17 revenue of US $67.3MM, +1.8% vs. 2Q16, and 1H17 revenue of $136.8MM, +4.1% vs. 1H16.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Joint Reconstruction | $65.3 | $61.8 | $3.5 | 5.6% |
| Knee | $21.5 | $21.5 | $0.0 | 0.2% |
| Hip | $12.5 | $13.4 | -$1.0 | -7.2% |
| Extremities | $31.3 | $27.0 | $4.4 | 16.3% |
| Spine | $0.0 | $2.0 | -$2.0 | -100.0% |
| Orthobiologics | $2.0 | $2.3 | -$0.3 | -13.3% |
| Total | $67.3 | $66.1 | $1.2 | 1.8% |
| 1H17 | 1H16 | $ Change | % Change | |
| Joint Reconstruction | $132.6 | $122.9 | $9.7 | 7.9% |
| Knee | $43.6 | $43.3 | $0.3 | 0.8% |
| Hip | $25.6 | $25.8 | -$0.2 | -0.8% |
| Extremities | $63.4 | $53.8 | $9.6 | 17.8% |
| Spine | $0.3 | $3.8 | -$3.5 | -92.5% |
| Orthobiologics | $3.9 | $4.7 | -$0.8 | -16.9% |
| Total | $136.8 | $131.4 | $5.4 | 4.1%* |
*Excluding the impact of divested spine products, 1H17 growth would be 7%
2Q17 Geographic results: U.S. $45.6MM, +2.4%; ex-U.S. $21.6MM, +0.6%
Performance highlights:
- Recon extremities growth benefited somewhat from Vantage ankle pilot launch, as well as the Equinoxe Preserve humeral stem
- Hips negatively affected by price pressure and certain ex-U.S. distribution transitions: changing out a distributor, in one instance, and changing a business model in another
- Knee revenue offset by price decreases
- Ongoing pilot launches of Truliant knee, Alteon HA hip stem and ExactechGPS shoulder application progressing well
- Completed first Truliant procedures in mid-2Q, now over 150 surgeries in; logged first Equinoxe Preserve and Alteon hip stem procedures by quarter’s end
- In 2H17, will build inventory for Truliant knee, pursuing full launch by year-end
- At the very end of the quarter, entered pilot launch for ExactechGPS TKA PLUS
- Rotating Bearing Knee is still with FDA – no further updates yet
- Announced first clinical use in Japan of recently-approved systems, including the Optetrak Logic CR knee, Novation Crown Cup, Alteon Tapered Wedge Stem and Equinoxe Reverse Shoulder
- After quarter’s close, entered an agreement to sell 100% of its investment in Exactech Medical Shanghai to Double Medical Technology for cash proceeds of $1.6MM; at closing—expected in 2H17—will enter into a distribution agreement for Double Medical to market Exactech’s products in China
Source: Exactech, Inc.; Form 10-Q, SEC.gov
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
